| ID | 1143 |
| Name of the vaccine | VAXNEUVANCE |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 18 years and older |
| Description of the vaccine | Pneumococcal 15-valent conjugate vaccine. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | United States |
| Year of manufacture | 2021 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | Opsonophagocytic killing of S. pneumoniae. |
| Route of administration | Intramuscular |
| Indications | Disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | NA |
| Side effects of vaccine | Injection-site pain, swelling and erythema, fatigue, myalgia, headache and arthralgia. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/150819/download |
| Other name | NA |
| Additional Links | NA
|